The Colossal Hoax: Obama’s Birth Certificate (Looks

New Post Public Reply Private Reply Replies (1) Message Board
Lmcat
271
The Colossal Hoax: Obama’s Birth Certificate

(Looks like there are more birthers around.)

WHEN WILL THE “BORN IN HAWAII” NARRATIVE FALL APART, JUST AS “COLLUSION” DID?

(Mar. 25, 2019) — On Friday evening, Special Counsel Robert Mueller delivered a report to the Justice Department completing his 22-month investigation into allegations of “collusion” between Donald Trump’s 2016 presidential campaign and Russia as well as Russian interference in that election.

Although not yet reviewed by Attorney General William Barr, news reports then indicated Mueller had recommended no additional indictments and, as a result, that no “collusion” was found.

That conclusion was verified Sunday when Barr sent a letter to leaders of the House and Senate Judiciary Committees summarizing the Special Counsel’s report, which by law is “confidential.”

Many in the media immediately appeared unwilling to believe Mueller’s conclusions. While one insisted that the issue would not be resolved until the 2020 presidential election, others immediately looked to investigations they alleged are taking place in the Southern District of New York (SDNY) extending to Trump and the Trump Organization.

Democrat members of Congress reacted by stating that they question Barr’s impartiality in determining, along with Deputy Attorney General Rod Rosenstein, that Trump did not commit “obstruction of justice.” Democrats, along with many Republicans, have consistently called for a release of the entire Mueller report, although the statute prohibits the release of grand jury testimony, classified information, and documentation which could damage an innocent person’s reputation.

Given that Mueller’s investigation, which interviewed 500 witnesses, issued 2800 subpoenas, and generated a lawsuit and criminal complaint from one of those witnesses, identified no evidence of a crime, some Americans are questioning how the mainstream media could have continued to fuel the narrative that “the walls are closing in” on Donald Trump for more than two years.

However, the media has been perpetrating a similar hoax for much longer. In February 2007, a first-term U.S. senator from Illinois declared his candidacy for the presidency amidst credible reports that he was born in Kenya or Indonesia. The media quickly closed ranks and derided anyone referring to the very reports it had generated not long before.

When an image was uploaded to the White House website on April 27, 2011, the media, without questioning or having it examined by experts, accepted it as proof that Barack Hussein Obama was born in Hawaii and was therefore eligible to hold the office of president.

The few outlets, bloggers and Americans who did question the image and Obama’s constitutional eligibility, among them Donald Trump, became objects of vicious verbal attacks, ridicule, and threats.

With rare exceptions, the media failed to ask why a Perkins Coie attorney was dispatched to the Hawaii Department of Health (HDOH) to obtain the alleged two certified copies of Obama’s original “long-form” birth certificate when Obama could have simply ordered them online, if the original existed, for a fee of $20, or communicated with the Health Department directly.

After the launch of a criminal investigation under the auspices of the Maricopa County Sheriff Office (MCSO) and its finding that the long-form image is a “computer-generated forgery,” the media again circled the wagons and attacked the messengers in the persons of lead investigator Mike Zullo and then-MCSO Sheriff Joseph Arpaio.

The media again did its best to bury the story when in December 2016, Zullo revealed that two forensic experts, each approaching its examination of the image from a different discipline, concluded that it cannot possibly be authentic.

While the media worked assiduously to keep the Russia “collusion” narrative alive, it worked equally hard to perpetuate the myth that what the Obama White House released was an authentic representation of a real, paper document when Zullo and Arpaio have said for more than seven years that it is not.

If the U.S. intelligence community was able to fabricate evidence implicating Donald Trump and several of his campaign associates in wrongdoing, turning their lives upside-down and bankrupting them with litigation costs, it was able to create the myth — and the “document” behind it — that Barack Hussein Obama was born in Honolulu, HI on August 4, 1961 and that the Hawaii Department of Health holds an original, “long-form” birth certificate within its archives.

That narrative is contrary to Zullo’s August report on Carl Gallups’s “Freedom Friday” in which Zullo said that two members of the same intelligence community informed him that it is “an open secret” that Obama was not born in the United States and cannot meet that pillar of the “natural born Citizen” requirement contained in Article II, Section 1, clause 5 of the U.S. Constitution.

More recently, Zullo reported that a high-ranking individual within the Trump administration was briefed on the evidence Arpaio and he collected over the 5+ years of the investigation, which also found Obama’s Selective Service registration form to be fraudulent.

House Intelligence Committee ranking member Devin Nunes has called for legal action against media entities which constantly churned out what he said were “fake news stories” on the “hoax” surrounding the Russia collusion narrative. Is it not time to hold the media accountable for perpetrating the colossal hoax of Obama’s eligibility?

https://www.thepostemail.com/2019/03/25/the-c...knADqPvd-s

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 23

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 32

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kotak Mahindra Bank's Innovative Tech Strategies

Updated Category News Views 587

Kotak Mahindra Bank's Commitment to Digital Transformation Kotak Mahindra Bank is at the forefront of revolutionizing financial services through its innovative technology strategies. Their latest report dives deep into the bank's extensive tech activities, highlighting how it leverages digital transformation to enhance customer experience and streamline operations....

Continue Reading
Star Group, L.P. Reflects on Fiscal 2024 Performance Updates

Updated Category News Views 349

Star Group's Fiscal 2024 Insights and Performance Analysis As the fiscal year wraps up, Star Group, L.P. (NYSE: SGU), a respected home energy distributor, shares its financial performance that ended on September 30, 2024. Amidst the prevailing challenges in the energy market, the company continues its commitment to delivering quality services while adapting to market...

Continue Reading
Krystal Biotech Launches Clinical Trial for Eye Therapy KB801

Updated Category News Views 148

Krystal Biotech Begins Phase 1/2 Trial of KB801 Krystal Biotech, Inc. (NASDAQ: KRYS) has recently announced exciting developments in its ophthalmology pipeline with the initiation of a Phase 1/2 clinical trial for KB801, aimed at treating neurotrophic keratitis (NK). This 2:1 randomized, double-masked, multicenter, placebo-controlled study, named EMERALD-1, marks a...

Continue Reading
Key Updates on the Annual General Meeting of Ignitis Group

Updated Category News Views 163

Exciting Updates for the Ignitis Group Shareholders The retained earnings figure for AB “Ignitis grup?” has been amended for the upcoming Annual General Meeting. It now stands at EUR 320,319,368.41, following a revision made only to the English version of the document. This adjustment reflects the company’s commitment to transparency and accuracy in their financial...

Continue Reading
Transforming Connectivity: The Future of mmWave Sensors Growth

Updated Category News Views 104

The mmWave sensors market was set on a blistering growth path back in 2023, valued at around USD 0.25 billion. By the time you fast-forward to 2032, projections had it skyrocketing to USD 2.40 billion, boasting a staggering CAGR of 28.59% from 2024 through 2032. You'd think this kind of momentum would have traders buzzing—oh wait, they were, especially as the push for...

Continue Reading